Patents Assigned to Quest Diagnostics Investments Incorporated
  • BCR-ABL1 splice variants and uses thereof
    Patent number: 9957574
    Abstract: The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 1, 2018
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: Wanlong Ma
  • CYSTIC FIBROSIS GENE MUTATIONS
    Publication number: 20180094321
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 5, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Matthew J. McGinniss, Arlene M. Buller, Franklin Quan, Mei Peng, Weimin Sun
  • Systems and methods for electronically distributing information
    Patent number: 9929985
    Abstract: Embodiments of the invention include systems and methods for transmitting messages related to certain information while maintaining the confidentiality of that information. A potential recipient may register one or more devices for receipt of such messages while specifying rules regarding when different messages may be delivered to the various devices. To keep sensitive information confidential, the messages may include only a link to such sensitive information, but exclude the sensitive information itself. An authorized recipient may then use the link to access the sensitive information via a password-protected Web site.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 27, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Douglas Menkedick, David Rapperport, Maheswar Putta
  • GRAPHICAL PRESENTATION OF MEDICAL DATA
    Publication number: 20180082018
    Abstract: Methods and user interfaces are provided for the display of data comprising series of data over time, with particular application to medical laboratory results and prescriptions of medication. A user may view multiple results simultaneously in a single display, with the abilities to zoom the time scale in and out and to select the time period for which results are displayed. Multiple displayed items of data may be selected for simultaneous display along a common time axis in a zoomable graph, facilitating interpretation of relationships between and/or among data items.
    Type: Application
    Filed: January 21, 2015
    Publication date: March 22, 2018
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: Kavya Ramachandran
  • Mass spectrometry assay for congenital adrenal hyperplasia
    Patent number: 9921231
    Abstract: Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 20, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Amit Ghoshal, Nigel J. Clarke, Mildred M. Goldman
  • Thyroglobulin quantitation by mass spectroscopy
    Patent number: 9915663
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: March 13, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Detection of gene fusions by intragenic differential expression (IDE) using average cycle thresholds
    Patent number: 9914973
    Abstract: Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene. The average expression of the 5? portion of the target gene is compared with the average expression of the 3? portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: March 13, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Shih-Min Cheng
  • Cystic fibrosis transmembrane conductance regulator gene mutations
    Patent number: 9909183
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: March 6, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Weimin Sun, Matthew J. McGinniss, Donghui Huang, Arlene Buller, Raymond Fenwick, Mei Peng, Franklin Quan
  • ALIGNMENT AND VARIANT SEQUENCING ANALYSIS PIPELINE
    Publication number: 20180051329
    Abstract: Provided are systems and methods for analyzing genetic sequence data from next generation sequence (NGS) platforms. Also provided are methods for the preparation of samples for nucleic acid sequence analysis by NGS. Variant calling is performed with a modified GATK variant caller. Mapping the reads to a genomic reference sequence is performed with a Burrows Wheeler Aligner (BWA) and does not comprise soft clipping. The genomic reference sequence is GRCh37.1 human genome reference. The sequencing method comprises emulsion PCR (emPCR), rolling circle amplification, or solid-phase amplification. In some embodiments, the solid-phase amplification is clonal bridge amplification.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 22, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Christopher Elzinga
  • KITS FOR DETECTING MYCOBACTERIUM AVIUM/INTRACELLULARE NUCLEIC ACID
    Publication number: 20180037938
    Abstract: Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the mig gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare.
    Type: Application
    Filed: October 23, 2017
    Publication date: February 8, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Edgar ONG, Maurice Exner
  • C peptide detection by mass spectrometry
    Patent number: 9885724
    Abstract: Methods are described for measuring the amount of C peptide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying C peptide in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 6, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel Clarke, Zhaohui Chen
  • MPL MUTATIONS IN JAK2 V617F NEGATIVE PATIENTS WITH MYELOPROLIFERATIVE DISEASE
    Publication number: 20180031561
    Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
    Type: Application
    Filed: August 10, 2017
    Publication date: February 1, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Wanlong Ma, Maher Albitar
  • Methods for detecting vitamin D metabolites by mass spectrometry
    Patent number: 9880180
    Abstract: Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally are directed to ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 30, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel J. Clarke, Brett Holmquist, Gloria Kwang-Ja Lee, Richard E. Reitz
  • NUCLEIC ACID DETECTION COMBINING AMPLIFICATION WITH FRAGMENTATION
    Publication number: 20180023145
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 25, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
  • Kisspeptin-54 detection by tandem mass spectrometry
    Patent number: 9874569
    Abstract: Methods are described for measuring the amount of a kisspeptin-54-derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying a kisspeptin-54 derived peptides in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: January 23, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Cory E. Bystrom, Richard E. Reitz
  • Cystic fibrosis transmembrane conductance regulator gene mutations
    Patent number: 9863000
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 9, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Feras Hantash
  • BCR-ABL VARIANTS
    Publication number: 20180003714
    Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 4, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Maher Albitar
  • Circulating microRNA as a marker for hepatocellular carcinoma
    Patent number: 9840741
    Abstract: Provided herein are methods for the diagnosis, or management of liver diseases, e.g. hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: December 12, 2017
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Kevin Qu, Ke Zhang, Maher Albitar
  • Cystic fibrosis gene mutations
    Patent number: 9840740
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: December 12, 2017
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Matthew J. McGinniss, Arlene M. Buller, Franklin Quan, Mei Peng, Weimin Sun
  • Quantitation of tamoxifen and metabolites thereof by mass spectrometry
    Patent number: 9835606
    Abstract: Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of norendoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and tamoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, norendoxifen, and other tamoxifen metabolites.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: December 5, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Nigel Clarke